Factors Associated With Major Bleeding Events

Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar ris...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2014-03, Vol.63 (9), p.891-900
Hauptverfasser: Goodman, Shaun G., MD, MSc, Wojdyla, Daniel M., MS, Piccini, Jonathan P., MD, White, Harvey D., MB, ChB, DSc, Paolini, John F., MD, PhD, Nessel, Christopher C., MD, Berkowitz, Scott D., MD, Mahaffey, Kenneth W., MD, Patel, Manesh R., MD, Sherwood, Matthew W., MD, Becker, Richard C., MD, Halperin, Jonathan L., MD, Hacke, Werner, MD, Singer, Daniel E., MD, Hankey, Graeme J., MD, Breithardt, Gunter, MD, Fox, Keith A.A., MB, ChB, Califf, Robert M., MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 900
container_issue 9
container_start_page 891
container_title Journal of the American College of Cardiology
container_volume 63
creator Goodman, Shaun G., MD, MSc
Wojdyla, Daniel M., MS
Piccini, Jonathan P., MD
White, Harvey D., MB, ChB, DSc
Paolini, John F., MD, PhD
Nessel, Christopher C., MD
Berkowitz, Scott D., MD
Mahaffey, Kenneth W., MD
Patel, Manesh R., MD
Sherwood, Matthew W., MD
Becker, Richard C., MD
Halperin, Jonathan L., MD
Hacke, Werner, MD
Singer, Daniel E., MD
Hankey, Graeme J., MD
Breithardt, Gunter, MD
Fox, Keith A.A., MB, ChB
Califf, Robert M., MD
description Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant bleeding (principal safety endpoint) with rivaroxaban and warfarin. Methods The risk of the principal safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors associated with major bleeding were examined in a multivariable model. Results The principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/100 patient-years; hazard ratio: 1.03; 95% confidence interval: 0.96 to 1.11). Major bleeding risk increased with age, but there were no differences between treatments in each age category (
doi_str_mv 10.1016/j.jacc.2013.11.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1645324143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0735109713062086</els_id><sourcerecordid>3557385571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-f3bdeb53bfaf6b3b30b088534b74d4809380ee42f0cfcdb8517f13b0e0cd6daa3</originalsourceid><addsrcrecordid>eNp9kE1Lw0AURQdRsFb_gKuA68T3Mpl8gAi1tCpUXKi4HGYmLzoxJnUmLfTfm1BBcOHqbu55H4exc4QIAdPLOqqVMVEMyCPEaIgDNkEh8pCLIjtkE8i4CBGK7JideF8DQJpjMWHhUpm-cz6Yed8Zq3oqg1fbvwcPqu5ccNMQlbZ9CxZbant_yo4q1Xg6-8kpe1kunud34erx9n4-W4WGi6wPK65L0oLrSlWp5pqDhjwXPNFZUiY5FDwHoiSuwFSm1LnArEKugcCUaakUn7KL_dy167425HtZdxvXDislpongcYIJH1rxvmVc572jSq6d_VRuJxHkqEXWctQiRy0SUQ4xQFd7iIb7t5ac9MZSa4Y3HZlelp39H7_-g5vGttao5oN25H_PlD6WIJ9G76N25JDGkKf8G4mnfvY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645324143</pqid></control><display><type>article</type><title>Factors Associated With Major Bleeding Events</title><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Goodman, Shaun G., MD, MSc ; Wojdyla, Daniel M., MS ; Piccini, Jonathan P., MD ; White, Harvey D., MB, ChB, DSc ; Paolini, John F., MD, PhD ; Nessel, Christopher C., MD ; Berkowitz, Scott D., MD ; Mahaffey, Kenneth W., MD ; Patel, Manesh R., MD ; Sherwood, Matthew W., MD ; Becker, Richard C., MD ; Halperin, Jonathan L., MD ; Hacke, Werner, MD ; Singer, Daniel E., MD ; Hankey, Graeme J., MD ; Breithardt, Gunter, MD ; Fox, Keith A.A., MB, ChB ; Califf, Robert M., MD</creator><creatorcontrib>Goodman, Shaun G., MD, MSc ; Wojdyla, Daniel M., MS ; Piccini, Jonathan P., MD ; White, Harvey D., MB, ChB, DSc ; Paolini, John F., MD, PhD ; Nessel, Christopher C., MD ; Berkowitz, Scott D., MD ; Mahaffey, Kenneth W., MD ; Patel, Manesh R., MD ; Sherwood, Matthew W., MD ; Becker, Richard C., MD ; Halperin, Jonathan L., MD ; Hacke, Werner, MD ; Singer, Daniel E., MD ; Hankey, Graeme J., MD ; Breithardt, Gunter, MD ; Fox, Keith A.A., MB, ChB ; Califf, Robert M., MD ; ROCKET AF Investigators</creatorcontrib><description>Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant bleeding (principal safety endpoint) with rivaroxaban and warfarin. Methods The risk of the principal safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors associated with major bleeding were examined in a multivariable model. Results The principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/100 patient-years; hazard ratio: 1.03; 95% confidence interval: 0.96 to 1.11). Major bleeding risk increased with age, but there were no differences between treatments in each age category (&lt;65, 65 to 74, ≥75 years; pinteraction  = 0.59). Compared with those without (n = 13,455), patients with a major bleed (n = 781) were more likely to be older, current/prior smokers, have prior gastrointestinal (GI) bleeding, mild anemia, and a lower calculated creatinine clearance and less likely to be female or have a prior stroke/transient ischemic attack. Increasing age, baseline diastolic blood pressure (DBP) ≥90 mm Hg, history of chronic obstructive pulmonary disease or GI bleeding, prior acetylsalicylic acid use, and anemia were independently associated with major bleeding risk; female sex and DBP &lt;90 mm Hg were associated with a decreased risk. Conclusions Rivaroxaban and warfarin had similar risk for major/nonmajor clinically relevant bleeding. Age, sex, DBP, prior GI bleeding, prior acetylsalicylic acid use, and anemia were associated with the risk of major bleeding. (An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: NCT00403767 )</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2013.11.013</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Anticoagulants ; atrial fibrillation ; Blood pressure ; Cardiac arrhythmia ; Cardiology ; Cardiovascular ; Confidence intervals ; Diabetes ; Drug dosages ; Drug therapy ; Embolisms ; Heart failure ; hemorrhage ; Hepatitis ; Hypertension ; Internal Medicine ; Nervous system ; Older people ; Risk factors ; Stroke</subject><ispartof>Journal of the American College of Cardiology, 2014-03, Vol.63 (9), p.891-900</ispartof><rights>American College of Cardiology Foundation</rights><rights>2014 American College of Cardiology Foundation</rights><rights>Copyright Elsevier Limited Mar 11, 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-f3bdeb53bfaf6b3b30b088534b74d4809380ee42f0cfcdb8517f13b0e0cd6daa3</citedby><cites>FETCH-LOGICAL-c357t-f3bdeb53bfaf6b3b30b088534b74d4809380ee42f0cfcdb8517f13b0e0cd6daa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jacc.2013.11.013$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids></links><search><creatorcontrib>Goodman, Shaun G., MD, MSc</creatorcontrib><creatorcontrib>Wojdyla, Daniel M., MS</creatorcontrib><creatorcontrib>Piccini, Jonathan P., MD</creatorcontrib><creatorcontrib>White, Harvey D., MB, ChB, DSc</creatorcontrib><creatorcontrib>Paolini, John F., MD, PhD</creatorcontrib><creatorcontrib>Nessel, Christopher C., MD</creatorcontrib><creatorcontrib>Berkowitz, Scott D., MD</creatorcontrib><creatorcontrib>Mahaffey, Kenneth W., MD</creatorcontrib><creatorcontrib>Patel, Manesh R., MD</creatorcontrib><creatorcontrib>Sherwood, Matthew W., MD</creatorcontrib><creatorcontrib>Becker, Richard C., MD</creatorcontrib><creatorcontrib>Halperin, Jonathan L., MD</creatorcontrib><creatorcontrib>Hacke, Werner, MD</creatorcontrib><creatorcontrib>Singer, Daniel E., MD</creatorcontrib><creatorcontrib>Hankey, Graeme J., MD</creatorcontrib><creatorcontrib>Breithardt, Gunter, MD</creatorcontrib><creatorcontrib>Fox, Keith A.A., MB, ChB</creatorcontrib><creatorcontrib>Califf, Robert M., MD</creatorcontrib><creatorcontrib>ROCKET AF Investigators</creatorcontrib><title>Factors Associated With Major Bleeding Events</title><title>Journal of the American College of Cardiology</title><description>Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant bleeding (principal safety endpoint) with rivaroxaban and warfarin. Methods The risk of the principal safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors associated with major bleeding were examined in a multivariable model. Results The principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/100 patient-years; hazard ratio: 1.03; 95% confidence interval: 0.96 to 1.11). Major bleeding risk increased with age, but there were no differences between treatments in each age category (&lt;65, 65 to 74, ≥75 years; pinteraction  = 0.59). Compared with those without (n = 13,455), patients with a major bleed (n = 781) were more likely to be older, current/prior smokers, have prior gastrointestinal (GI) bleeding, mild anemia, and a lower calculated creatinine clearance and less likely to be female or have a prior stroke/transient ischemic attack. Increasing age, baseline diastolic blood pressure (DBP) ≥90 mm Hg, history of chronic obstructive pulmonary disease or GI bleeding, prior acetylsalicylic acid use, and anemia were independently associated with major bleeding risk; female sex and DBP &lt;90 mm Hg were associated with a decreased risk. Conclusions Rivaroxaban and warfarin had similar risk for major/nonmajor clinically relevant bleeding. Age, sex, DBP, prior GI bleeding, prior acetylsalicylic acid use, and anemia were associated with the risk of major bleeding. (An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: NCT00403767 )</description><subject>Anticoagulants</subject><subject>atrial fibrillation</subject><subject>Blood pressure</subject><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Cardiovascular</subject><subject>Confidence intervals</subject><subject>Diabetes</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Embolisms</subject><subject>Heart failure</subject><subject>hemorrhage</subject><subject>Hepatitis</subject><subject>Hypertension</subject><subject>Internal Medicine</subject><subject>Nervous system</subject><subject>Older people</subject><subject>Risk factors</subject><subject>Stroke</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kE1Lw0AURQdRsFb_gKuA68T3Mpl8gAi1tCpUXKi4HGYmLzoxJnUmLfTfm1BBcOHqbu55H4exc4QIAdPLOqqVMVEMyCPEaIgDNkEh8pCLIjtkE8i4CBGK7JideF8DQJpjMWHhUpm-cz6Yed8Zq3oqg1fbvwcPqu5ccNMQlbZ9CxZbant_yo4q1Xg6-8kpe1kunud34erx9n4-W4WGi6wPK65L0oLrSlWp5pqDhjwXPNFZUiY5FDwHoiSuwFSm1LnArEKugcCUaakUn7KL_dy167425HtZdxvXDislpongcYIJH1rxvmVc572jSq6d_VRuJxHkqEXWctQiRy0SUQ4xQFd7iIb7t5ac9MZSa4Y3HZlelp39H7_-g5vGttao5oN25H_PlD6WIJ9G76N25JDGkKf8G4mnfvY</recordid><startdate>20140311</startdate><enddate>20140311</enddate><creator>Goodman, Shaun G., MD, MSc</creator><creator>Wojdyla, Daniel M., MS</creator><creator>Piccini, Jonathan P., MD</creator><creator>White, Harvey D., MB, ChB, DSc</creator><creator>Paolini, John F., MD, PhD</creator><creator>Nessel, Christopher C., MD</creator><creator>Berkowitz, Scott D., MD</creator><creator>Mahaffey, Kenneth W., MD</creator><creator>Patel, Manesh R., MD</creator><creator>Sherwood, Matthew W., MD</creator><creator>Becker, Richard C., MD</creator><creator>Halperin, Jonathan L., MD</creator><creator>Hacke, Werner, MD</creator><creator>Singer, Daniel E., MD</creator><creator>Hankey, Graeme J., MD</creator><creator>Breithardt, Gunter, MD</creator><creator>Fox, Keith A.A., MB, ChB</creator><creator>Califf, Robert M., MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20140311</creationdate><title>Factors Associated With Major Bleeding Events</title><author>Goodman, Shaun G., MD, MSc ; Wojdyla, Daniel M., MS ; Piccini, Jonathan P., MD ; White, Harvey D., MB, ChB, DSc ; Paolini, John F., MD, PhD ; Nessel, Christopher C., MD ; Berkowitz, Scott D., MD ; Mahaffey, Kenneth W., MD ; Patel, Manesh R., MD ; Sherwood, Matthew W., MD ; Becker, Richard C., MD ; Halperin, Jonathan L., MD ; Hacke, Werner, MD ; Singer, Daniel E., MD ; Hankey, Graeme J., MD ; Breithardt, Gunter, MD ; Fox, Keith A.A., MB, ChB ; Califf, Robert M., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-f3bdeb53bfaf6b3b30b088534b74d4809380ee42f0cfcdb8517f13b0e0cd6daa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Anticoagulants</topic><topic>atrial fibrillation</topic><topic>Blood pressure</topic><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Cardiovascular</topic><topic>Confidence intervals</topic><topic>Diabetes</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Embolisms</topic><topic>Heart failure</topic><topic>hemorrhage</topic><topic>Hepatitis</topic><topic>Hypertension</topic><topic>Internal Medicine</topic><topic>Nervous system</topic><topic>Older people</topic><topic>Risk factors</topic><topic>Stroke</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goodman, Shaun G., MD, MSc</creatorcontrib><creatorcontrib>Wojdyla, Daniel M., MS</creatorcontrib><creatorcontrib>Piccini, Jonathan P., MD</creatorcontrib><creatorcontrib>White, Harvey D., MB, ChB, DSc</creatorcontrib><creatorcontrib>Paolini, John F., MD, PhD</creatorcontrib><creatorcontrib>Nessel, Christopher C., MD</creatorcontrib><creatorcontrib>Berkowitz, Scott D., MD</creatorcontrib><creatorcontrib>Mahaffey, Kenneth W., MD</creatorcontrib><creatorcontrib>Patel, Manesh R., MD</creatorcontrib><creatorcontrib>Sherwood, Matthew W., MD</creatorcontrib><creatorcontrib>Becker, Richard C., MD</creatorcontrib><creatorcontrib>Halperin, Jonathan L., MD</creatorcontrib><creatorcontrib>Hacke, Werner, MD</creatorcontrib><creatorcontrib>Singer, Daniel E., MD</creatorcontrib><creatorcontrib>Hankey, Graeme J., MD</creatorcontrib><creatorcontrib>Breithardt, Gunter, MD</creatorcontrib><creatorcontrib>Fox, Keith A.A., MB, ChB</creatorcontrib><creatorcontrib>Califf, Robert M., MD</creatorcontrib><creatorcontrib>ROCKET AF Investigators</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goodman, Shaun G., MD, MSc</au><au>Wojdyla, Daniel M., MS</au><au>Piccini, Jonathan P., MD</au><au>White, Harvey D., MB, ChB, DSc</au><au>Paolini, John F., MD, PhD</au><au>Nessel, Christopher C., MD</au><au>Berkowitz, Scott D., MD</au><au>Mahaffey, Kenneth W., MD</au><au>Patel, Manesh R., MD</au><au>Sherwood, Matthew W., MD</au><au>Becker, Richard C., MD</au><au>Halperin, Jonathan L., MD</au><au>Hacke, Werner, MD</au><au>Singer, Daniel E., MD</au><au>Hankey, Graeme J., MD</au><au>Breithardt, Gunter, MD</au><au>Fox, Keith A.A., MB, ChB</au><au>Califf, Robert M., MD</au><aucorp>ROCKET AF Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors Associated With Major Bleeding Events</atitle><jtitle>Journal of the American College of Cardiology</jtitle><date>2014-03-11</date><risdate>2014</risdate><volume>63</volume><issue>9</issue><spage>891</spage><epage>900</epage><pages>891-900</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant bleeding (principal safety endpoint) with rivaroxaban and warfarin. Methods The risk of the principal safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors associated with major bleeding were examined in a multivariable model. Results The principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/100 patient-years; hazard ratio: 1.03; 95% confidence interval: 0.96 to 1.11). Major bleeding risk increased with age, but there were no differences between treatments in each age category (&lt;65, 65 to 74, ≥75 years; pinteraction  = 0.59). Compared with those without (n = 13,455), patients with a major bleed (n = 781) were more likely to be older, current/prior smokers, have prior gastrointestinal (GI) bleeding, mild anemia, and a lower calculated creatinine clearance and less likely to be female or have a prior stroke/transient ischemic attack. Increasing age, baseline diastolic blood pressure (DBP) ≥90 mm Hg, history of chronic obstructive pulmonary disease or GI bleeding, prior acetylsalicylic acid use, and anemia were independently associated with major bleeding risk; female sex and DBP &lt;90 mm Hg were associated with a decreased risk. Conclusions Rivaroxaban and warfarin had similar risk for major/nonmajor clinically relevant bleeding. Age, sex, DBP, prior GI bleeding, prior acetylsalicylic acid use, and anemia were associated with the risk of major bleeding. (An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: NCT00403767 )</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/j.jacc.2013.11.013</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0735-1097
ispartof Journal of the American College of Cardiology, 2014-03, Vol.63 (9), p.891-900
issn 0735-1097
1558-3597
language eng
recordid cdi_proquest_journals_1645324143
source Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Anticoagulants
atrial fibrillation
Blood pressure
Cardiac arrhythmia
Cardiology
Cardiovascular
Confidence intervals
Diabetes
Drug dosages
Drug therapy
Embolisms
Heart failure
hemorrhage
Hepatitis
Hypertension
Internal Medicine
Nervous system
Older people
Risk factors
Stroke
title Factors Associated With Major Bleeding Events
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T06%3A46%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20Associated%20With%20Major%20Bleeding%20Events&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Goodman,%20Shaun%20G.,%20MD,%20MSc&rft.aucorp=ROCKET%20AF%20Investigators&rft.date=2014-03-11&rft.volume=63&rft.issue=9&rft.spage=891&rft.epage=900&rft.pages=891-900&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/j.jacc.2013.11.013&rft_dat=%3Cproquest_cross%3E3557385571%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645324143&rft_id=info:pmid/&rft_els_id=1_s2_0_S0735109713062086&rfr_iscdi=true